Bristol-Myers Squibb on Wednesday said it cut a deal with two generic drugmakers to allow cheap versions of its newest AIDS drug to be made in sub-Saharan Africa and India, where millions suffer from the disease. Bristol-Myers said it will license and lend technical expertise for its drug Reyataz to generic manufacturers Aspen PharmaCare of South Africa and Emcure Pharmaceuticals of India. [also refers to Roche]